95 - References

References

Depression and anxiety disorders CHAPTER 3 12. Briscoe VJ, et al. Effects of a selective serotonin reuptake inhibitor, fluoxetine, on counterregulatory responses to hypoglycemia in healthy individuals. Diabetes 2008; 57:2453–2460. 13. Andersohn F, et al. Long-­term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009; 166:591–598. 14. Kivimaki M, et al. Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-­based study. Diabetes Care 2010; 33:2611–2616. 15. Rubin RR, et al. Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study. Diabetes Care 2010; 33:2549–2551. 16. Echeverry D, et al. Effect of pharmacological treatment of depression on A1C and quality of life in low-­income Hispanics and African Americans with diabetes: a randomized, double-­blind, placebo-­controlled trial. Diabetes Care 2009; 32:2156–2160. 17. Dhavale HS, et al. Depression and diabetes: impact of antidepressant medications on glycaemic control. J Assoc Physicians India 2013; 61:896-­899. 18. Mojtabai R. Antidepressant use and glycemic control. Psychopharmacology (Berl) 2013; 227:467–477. 19. Srisurapanont M, et al. Antidepressants for depressed patients with type 2 diabetes mellitus: a systematic review and network meta-­analysis of short-­term randomized controlled trials. Neurosci Biobehav Rev 2022; 139:104731. 20. Nguyen TTH, et al. Role of serotonin transporter in antidepressant-­induced diabetes mellitus: a pharmacoepidemiological-­pharmacodynamic study in VigiBase(®). Drug Saf 2018; 41:1087–1096. 21. Dandjinou M, et al. Antidepressant use during pregnancy and the risk of gestational diabetes mellitus: a nested case–control study. BMJ Open 2019; 9:e025908. 22. Kuo HY, et al. Antidepressants and risk of type 2 diabetes mellitus: a population-­based nested case-­control study. J Clin Psychopharmacol 2020; 40:359–365. 23. Lustman PJ, et al. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-­blind, placebo-­controlled trial. Psychosom Med 1997; 59:241–250. 24. McIntyre RS, et al. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf 2006; 5:157–168. 25. Mumoli N, et al. Clomipramine-­induced diabetes. Ann Intern Med 2008; 149:595–596. 26. Goodnick PJ. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatry 2001; 13:31–41. 27. McIntyre RS, et al. Mood and psychotic disorders and type 2 diabetes: a metabolic triad. Can J Diabetes 2005; 29:122–132. 28. Raskin J, et al. Duloxetine versus routine care in the long-­term management of diabetic peripheral neuropathic pain. J Palliat Med 2006; 9:29–40. 29. Crucitti A, et al. Duloxetine treatment and glycemic controls in patients with diagnoses other than diabetic peripheral neuropathic pain: a meta-­analysis. Curr Med Res Opin 2010; 26:2579–2588. 30. Mekonnen AD, et al. Desvenlafaxine-­associated hyperglycemia: a case report and literature review. Ment Health Clin 2020; 10:85–89. 31. Song HR, et al. Does mirtazapine interfere with naturalistic diabetes treatment? J Clin Psychopharmacol 2014; 34:588–594. 32. Song HR, et  al. Effects of mirtazapine on patients undergoing naturalistic diabetes treatment: a follow-­up study extended from 6 to 12 months. J Clin Psychopharmacol 2015; 35:730–731. 33. Roopan S, et al. Use of antidepressants in patients with depression and comorbid diabetes mellitus: a systematic review. Acta Neuropsychiatr 2017; 29:127–139. 34. Baldwin DS, et al. Efficacy and safety of vortioxetine in treatment of patients with major depressive disorder and common co-­morbid physical illness. J Affect Disord 2022; 311:588–594. 35. Zhang Y, et al. Effect of metformin on the risk of depression: a systematic review and meta-­regression of observational studies. Asian J Psychiatry 2024; 92:103894. 36. Yang Y, et al. Metformin treatment improves depressive symptoms associated with type 2 diabetes: a 24-­week longitudinal study. J Affect Disord 2024; 365:80–86.